Please login to the form below

Not currently logged in
Email:
Password:

anti-PD-1

This page shows the latest anti-PD-1 news and features for those working in and with pharma, biotech and healthcare.

Merck closes in on adjuvant melanoma indication for Keytruda

Merck closes in on adjuvant melanoma indication for Keytruda

Keytruda isn’t the first PD-1 inhibitor to show activity in this setting. ... Two positive trials make it likely adjuvant anti-PD-1 will become standard of adjuvant care for high-risk melanoma, rather than Yervoy which is associated with much more

Latest news

  • MSD’s Keytruda wins bladder cancer indication in Japan MSD’s Keytruda wins bladder cancer indication in Japan

    MSD’ s Keytruda wins bladder cancer indication in Japan. Becomes first anti-PD1 approved in the country for previously treated UC. ... Baynes added: “We welcome the approval of Keytruda as the first anti-PD-1 therapy for these patients in Japan based

  • BMS’ Opdivo/Yervoy combination demonstrates OS benefit BMS’ Opdivo/Yervoy combination demonstrates OS benefit

    It found an overall survival benefit across programmed death ligand 1 (PD-L1) expression levels, which is how a patient responds to anti-PD-1/L1 antibodies. ... Renal cell carcinoma is the most common type of kidney cancer in adults, accounting for more

  • MSD touts Keytruda first-line promise in NSCLC MSD touts Keytruda first-line promise in NSCLC

    The firm has just released new, two-year follow up results from the Keynote-024 trial, which compared the anti PD-1/PD-L1 treatment to chemotherapy, showing a 37% reduction

  • MSD's Keytruda wins new bladder cancer indication in Europe MSD's Keytruda wins new bladder cancer indication in Europe

    Merck Sharp and Dohme’s (MSD) monoclonal anti-PD-1 therapy Keytruda (pembrolizumab) has won a new indication in Europe for patients with locally advanced or metastatic urothelial carcinoma (mUC), the

  • Solid start for Dupixent as Sanofi raises 2017 outlook Solid start for Dupixent as Sanofi raises 2017 outlook

    Brandicourt also pointed to the potential of Sanofi's pipeline, saying that "the initiation of phase III studies in additional indications for dupilumab, the phase II/III programs with the anti ... PD-1 in multiple cancer indications and fitusiran in

More from news
Approximately 3 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    Gilead has been trying to diversify away from anti-viral therapies into oncology and Kite is a good fit with its CAR-T technology and a lead product in priority review ... Licence to develop and commercialise. GLS-010, anti-PD-1 antibody in phase I for

  • The new launch paradigm The new launch paradigm

    Thousands of patients worldwide are in clinical trials with anti-PD-1 or anti-PD-L1 drugs produced by several pharmaceutical companies prior to the expected arrival of this new exciting

  • Deal Watch July 2016 Deal Watch July 2016

    At the other end of the development spectrum Servier paid the same amount upfront for the rights to Sorrento's immuno-oncology product: STI-A1110, an anti-PD-1 mAb, presently ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13) in

  • Deal Watch October 2015 Deal Watch October 2015

    Up to 3 anti-PD-1 based bispecific antibodies for oncology. Expansion of existing collaboration. ... Research collaboration, licence. 535. XOMA Corporation/ Novartis. Anti-transforming growth factor-beta (TGFb) antibody programme incl XOMA089 plus other

  • Pharma deals in September 2015 Pharma deals in September 2015

    Agenus will invest the proceeds in its growing pipeline of pre-clinical immuno-oncology treatments which include a series of PD-1 and CTLA-4 inhibitor programmes. ... Acquisition - company. 1, 230. Jiangsu Hengrui Medicine. Incyte. anti-PD-1, checkpoint

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics